Latest news with #ThermoFisherScientific
Globe and Mail
2 days ago
- Business
- Globe and Mail
Peptide Synthesis Market to Hit USD 1.41 Billion by 2029 with 11.7% CAGR
"Thermo Fisher Scientific Inc. is one of the dominant players in the peptide synthesis market. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of various growth strategies." The market for peptide synthesis market is competitive, with key players strategizing to capture the majority market share. Prominent players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Kaneka Corporation (Japan), GenScript (China) The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching US$ 0.81 Billion in 2024 and an impressive US$ 1.41 Billion by 2029. The peptide synthesis market is driven by the growing demand for therapeutic peptides in treating chronic diseases, including cancer, diabetes, and cardiovascular disorders. Advancements in solid-phase peptide synthesis (SPPS) and hybrid approaches have significantly improved efficiency, yield, and cost-effectiveness, fueling adoption in pharmaceutical R&D. The rise of personalized medicine has further expanded the need for custom peptide synthesis, supporting applications in targeted therapies and biomarker research. Emerging trends such as the integration of automation and AI-driven platforms among the instruments is further likely to fuel the market growth in coming years. Browse in-depth TOC on " Peptide Synthesis Market" 513 - Tables 55 - Figures 460 - Pages Based on offerings, the market is segmented into products and services. By-products market is further divided into consumables and instruments. Among these consumables dominated the peptide synthesis market. The consumables segment is further bifurcated into reagents and other consumables. The reagents market is further divided into resins, amino acids, coupling reagents, dyes & fluorescent labeling reagents, deprotection agents, cleavage reagents, and other reagents. In 2023, the resins segment accounted for the largest share of the peptide synthesis market. Resins play an important role in solid-phase peptide synthesis (SPPS), the most widely used method for peptide production. For instance, polystyrene-based and PEG-based resins are extensively used due to their high stability and scalability. The instruments segment is further divided into peptide synthesizers, chromatography equipment, lyophilizers, and others. The peptide synthesizer segment is further divided into automated and manual peptide synthesizers. Peptide synthesizers dominated the instruments market due to their ability to automate and streamline peptide production, making them essential for research and industrial applications. The growing demand for custom peptides in drug discovery, diagnostic research, and therapeutic applications has further boosted the adoption of advanced synthesizers. The services segment is further divided into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. The peptide synthesis segment dominated the services segment. The increasing adoption of peptides in emerging fields such as personalized medicine, vaccine development, and epigenetics drives demand for custom synthesis solutions, fostering growth in the segment. Based on technique, the peptide synthesis market is segmented into chemical and biological. The chemical segment is further divided into solid-phase peptide synthesis, solution-phase peptide synthesis, and others. The biological segment is divided into recombinant DNA technology and enzymes. The chemical segment dominated the market in 2023. The solid-phase peptide synthesis (SPPS) segment dominates the peptide synthesis market due to its efficiency, scalability, and widespread adoption in research and commercial applications. The dominance of SPPS is further driven by advancements in automation and reagent technologies, which have significantly reduced synthesis time and enhanced yield. Based on application, the market is divided into therapeutics, diagnostics, and research & development. Therapeutics by indication is further divided into cancer, diabetes, obesity, autoimmune disease, and other disease indications. Therapeutics by molecules is further segmented into peptide-based vaccines, peptide-drug conjugates (PDCs), peptide inhibitors, and other molecules. Therapeutic applications dominated the peptide synthesis market due to the growing demand for peptide-based drugs, which offer targeted and effective treatments with fewer side effects compared to traditional small molecules. The peptide synthesis market is segmented by end users into pharmaceutical and biotechnology companies, CDMOS & CROS, academic and research institutes, medical device companies, and hospitals and diagnostic centers. The pharmaceutical and biotechnology companies segment held the largest market share in 2023. The rise of peptide-based drugs and biologics has led to increased investments by pharmaceutical and biotech firms in peptide synthesis technologies, particularly in the production of therapeutic peptides for diseases such as cancer, diabetes, and autoimmune disorders. These factors are fueling the growth of the segment. The market is segmented by region into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the peptide synthesis market in 2023, and the Asia Pacific region is likely to grow at a significant CAGR during the forecast period. US-dominated North American peptide synthesis market owing to the presence of strong pharmaceutical and biotechnology companies in the country, advanced research infrastructure, and significant investments in drug discovery and development. The Asia Pacific region is anticipated to grow at a significant CAGR due to growing focus on personalized medicine and peptide-based therapeutics in the region fuels the demand for advanced peptide synthesis technologies. The market for peptide synthesis market is competitive, with key players strategizing to capture the majority market share. Prominent players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Kaneka Corporation (Japan), GenScript (China), and Bachem Holding AG (Switzerland), among others. The market players have adopted various organic and inorganic growth strategies, such as the development of advanced products, partnerships, agreements, expansions, and acquisitions to strengthen their position in the peptide synthesis market. Thermo Fisher Scientific Inc. is one of the dominant players in the peptide synthesis market. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of various growth strategies. The company offers a wide range of peptide synthesis products and services. The company has adopted different growth strategies, such as deals that include agreements, and acquisitions, to maintain its leading position in the peptide synthesis market. The company's strong customer support and extensive distribution network further solidify the company's leadership position in the market. Merck KGaA is a key player in the peptide synthesis market, leveraging its expertise in life sciences and advanced chemical technologies. The company's Novabiochem product line offers a broad range of high-quality reagents, resins, and building blocks essential for efficient and reliable peptide synthesis. Merck KGaA focuses on innovation supporting advanced techniques such as microwave-assisted synthesis, which significantly improves reaction efficiency and yield. The company's strategic partnerships and increased investments in biopharmaceutical R&D further enhance its competitive edge in the market. Merck's strong geographic presence and adoption of growth strategies further contribute to its dominance in the market. For more information, Inquire Now!
Yahoo
3 days ago
- Business
- Yahoo
Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine. Epigenetics Diagnostics Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays. Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders. Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 133 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $15.5 Billion Forecasted Market Value (USD) by 2034 $70.7 Billion Compound Annual Growth Rate 16.5% Regions Covered Global Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine. Epigenetics Diagnostics Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays. Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders. Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 133 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $15.5 Billion Forecasted Market Value (USD) by 2034 $70.7 Billion Compound Annual Growth Rate 16.5% Regions Covered Global Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
13-06-2025
- Business
- Yahoo
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities - - Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline - TORONTO, June 13, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. "It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity," said Doug Drysdale, Chief Executive Officer of Cybin. "With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development." Recent Corporate Highlights Continued to expand its strategic clinical site partnership ("SPA") program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows: U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ("IM") injection, including CYB004. Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Recent statements and hiring decisions by senior U.S. Health and Human Services ("HHS") and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a "top priority" and promised an "expeditious and rapid review" of clinical data.1 Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws.2 Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to "embrace" compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD.3 President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy.4 Cybin's Chief Executive Officer Doug Drysdale recently appeared on Fox News and is increasingly sought by media outlets as a trusted commentator.5 On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Panel Title: The Home Stretch: Pivotal Trials and Preparing for LaunchDate and Time: Thursday, June 19, 2025, at 9:30 a.m. MDT (11:30 a.m. EDT) About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Sources NewsNation, "FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority'," interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, (accessed June 9, 2025). Politico, "A Psychedelics Hire at HHS," newsletter article, published May 28 2025, (accessed June 9 2025). The Wall Street Journal, "Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It," news article, published May 17 2025, (accessed June 9 2025). The Associated Press, "Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love," news article, published May 14 2025, (accessed June 9 2025). Fox News. "Trump Administration Exploring Potential Benefits of Psychedelic Treatments." America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. View source version on Contacts Investor & Media: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities - - Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline - TORONTO, June 13, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. "It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity," said Doug Drysdale, Chief Executive Officer of Cybin. "With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development." Recent Corporate Highlights Continued to expand its strategic clinical site partnership ("SPA") program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows: U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ("IM") injection, including CYB004. Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Recent statements and hiring decisions by senior U.S. Health and Human Services ("HHS") and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a "top priority" and promised an "expeditious and rapid review" of clinical data.1 Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws.2 Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to "embrace" compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD.3 President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy.4 Cybin's Chief Executive Officer Doug Drysdale recently appeared on Fox News and is increasingly sought by media outlets as a trusted commentator.5 On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Panel Title: The Home Stretch: Pivotal Trials and Preparing for LaunchDate and Time: Thursday, June 19, 2025, at 9:30 a.m. MDT (11:30 a.m. EDT) About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Sources NewsNation, "FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority'," interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, (accessed June 9, 2025). Politico, "A Psychedelics Hire at HHS," newsletter article, published May 28 2025, (accessed June 9 2025). The Wall Street Journal, "Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It," news article, published May 17 2025, (accessed June 9 2025). The Associated Press, "Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love," news article, published May 14 2025, (accessed June 9 2025). Fox News. "Trump Administration Exploring Potential Benefits of Psychedelic Treatments." America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. View source version on Contacts Investor & Media: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
